机译:预测临床病理风险有限的受体阳性乳腺癌患者的遥感复发:使用PAM50在1478名后代患者的复发评分患者单独治疗辅助内分泌治疗
Department of Surgery and Comprehensive Cancer Center Medical University of Vienna Vienna Austria;
ABCSG Research Institute of Cancer Research and Comprehensive Cancer Center Medical University of;
IIIrd Medical Department Hematology Medical Oncology Hemostaseology Rheumatology and Infectious;
Division of Oncology Department of Internal Medicine Medical University of Graz Graz Austria;
Clinical Institute of Pathology and Comprehensive Cancer Center Medical University of Vienna;
Clinical Institute of Pathology and Comprehensive Cancer Center Medical University of Vienna;
IIIrd Medical Department Hematology Medical Oncology Hemostaseology Rheumatology and Infectious;
Department of Surgery State Hospital Wiener. Neustadt Wiener Neustadt Austria;
Department of Surgery Breast Cancer Center Hospital of the Sisters of Charity Linz Austria;
Department of Gynecology and Obstetrics and Comprehensive Cancer Center Medical University of;
Department of Surgery and Comprehensive Cancer Center Medical University of Vienna Vienna Austria;
Department of Surgery and Comprehensive Cancer Center Medical University of Vienna Vienna Austria;
Department of Surgery and Comprehensive Cancer Center Medical University of Vienna Vienna Austria;
Department of Internal Medicine I and Comprehensive Cancer Center Medical University of Vienna;
Department of Internal Medicine I and Comprehensive Cancer Center Medical University of Vienna;
Division of Oncology Department of Internal Medicine Medical University of Graz Graz Austria;
IIIrd Medical Department Hematology Medical Oncology Hemostaseology Rheumatology and Infectious;
NanoString Technologies Seattle United States;
NanoString Technologies Seattle United States;
NanoString Technologies Seattle United States;
MyRAQA Redwood Shores United States;
British Columbia Cancer Agency Vancouver Canada;
Austrian Breast and Colorectal Cancer Study Group Vienna Austria;
British Columbia Cancer Agency Vancouver Canada;
Clinical prognostic factors; Early breast cancer; Intrinsic subtypes; Metastasis prediction; Prognosis; Risk of Recurrence (ROR);
机译:临床病理风险有限的受体阳性乳腺癌患者的远处复发预测:使用ABCSG-8试验的1478名绝经后仅接受辅助内分泌治疗的患者中使用PAM50复发风险评分
机译:识别接受内分泌治疗的绝经后妇女淋巴结阳性激素受体阳性的早期乳腺癌的临床相关预后亚组:使用PAM50复发评分和内在亚型的风险对ABCSG-8和ATAC进行联合分析
机译:PAM50复发评分的风险预测,在综合丹麦群体综合妇女综合妇女群体分配给荷尔蒙受体阳性早期乳腺癌5年的综合丹麦群体中的10年遥远复发
机译:激光诱导热疗法(LITT)用于治疗乳腺癌患者的局部复发
机译:问题时间:对绝经后乳腺癌患者有关内分泌治疗的信息需求的研究。
机译:具有21种基因的RecurrenceScore®检测方法可预测接受基于表柔比星和多西紫杉醇或表柔比星的辅助序贯化疗的淋巴结阳性激素受体阳性乳腺癌患者的远处复发(PACS-01试验)
机译:预测近期内分泌治疗后的晚期复发:奥地利乳腺癌患者的综合分析8和Arimidex,单独或组合随机试验使用PAM50复发评分